Apoptosis is the primary mechanism through which most chemotherapeutic agents induce tumor cell death. The purpose of this study was to determine the extent to which blasts from children with leukemia undergo a uniform apoptotic death pathway in vivo. The expression of pro-and anti-apoptotic proteins p53, p21, MDM-2, BCL-2, BCL-X L , BCL-X S , and BAX, and caspase-3 activity was determined in circulating blasts collected from the peripheral blood of children with leukemia prior to, and at serial time points following chemotherapy. Culturing blasts ex vivo for 12 h assessed spontaneous apoptosis and the increment induced by chemotherapy. Baseline apoptosis varied between 3% and 29%. Twenty-four hours following chemotherapy the increase in the percentage of cells undergoing apoptosis ranged from Ͻ1% to 38%. Eleven of 20 patients who received initial treatment with a p53-dependent drug showed an increase in p53 expression. In these patients, the levels of p53 target genes were also increased. A uniform pattern of BCL-2 family protein expression was not observed and only a minority of samples showed a change that would favor apoptosis. We conclude that that the initial apoptotic response to chemotherapy in children with leukemia is variable involving both p53-dependent and p53-independent pathways.
Introduction
The outcome for children with acute lymphoblastic leukemia has improved dramatically over the past two decades. [1] [2] [3] [4] However, contemporary therapy is associated with many serious short-and long-term side-effects, and the prognosis for the 25% of children who fail treatment is poor. 5, 6 Thus, new approaches are needed to determine the most appropriate treatment at diagnosis, and to discover new therapeutic options for those with high-risk disease.
It has become increasingly clear that the efficacy of chemotherapeutic agents is dependent on their ability to initiate programmed cell death or apoptosis. 7 Apoptosis is an evolutionarily conserved, active, energy-dependent mechanism of cellular death and is regulated by the relative levels of both pro-and anti-apoptotic proteins. 8, 9 Understanding the apoptotic response to chemotherapy in vivo may provide insight into mechanisms of drug resistance. Future therapeutic applications might focus on modulating the expression of apoptotic proteins to promote rapid induction of tumor cell death.
A central component of the apoptotic response to cancer therapy is the p53 tumor suppressor protein. The p53 protein regulates the expression of many genes involved in cell cycle control, DNA repair and apoptosis. 10, 11 Alterations in the p53 pathway, through direct mutation and/or deletion, result in defective cellular responses after DNA damage, and contribute to resistance to diverse chemotherapeutic agents. 7, 12, 13 Moreover, functional p53 signaling may be inhibited by MDM-2, another transcriptional target of p53. High levels of MDM-2 have been noted in samples from children whose disease has been classified as high-risk for recurrence. 14, 15 Members of the BCL-2 protein family also play pivotal roles in the decision and execution phases of apoptosis. 16 To date, 15 BCL-2 family members have been identified as either pro-(eg BAX, BOK, BCL-X S , BID, BAD and Noxa) or anti-(eg BCL-2 and BCL-X L ) apoptotic proteins. Anti-apoptotic family members such as BCL-2 and BCL-X L have been shown to protect cancer cells from the effects of chemotherapy. [17] [18] [19] However, the prognostic significance of BCL-2-related protein levels remains uncertain. While some studies have shown that high levels of BCL-2 correlate with a poor outcome in follicular lymphoma, acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL), others do not demonstrate such an association. [20] [21] [22] Somewhat paradoxically, high levels of the pro-apoptotic protein, BAX, has been associated with an unfavorable outcome in ALL, while another report has demonstrated low BAX/BCL-2 ratios in blasts at relapse. 23, 24 The explanation for these divergent results is unclear but may be related to the fact that static levels of these proteins may be a poor reflection of changes that occur in response to therapy.
The terminal phases of the apoptotic response involve the caspase family of cysteine proteases. 25 These proteins exist as proenzymes and are activated autocatalytically, or by another caspase, forming a proteolytic cascade that dismantles cell integrity. Initiator caspases (eg caspase 9) can be activated through a mitochondrial pathway involving the release of cytochrome c or through a death receptor pathway (eg caspase 8).
26-29 BCL-2 proteins modulate apoptosis by influencing transmission of mitochondrial signals and/or by directly influencing the activation of initiator caspases. For example, BCL-2 prevents the release of cytochrome c from mitochondria while BCL-X L appears to inhibit the association of APAF-1 with procaspase 9. 30, 31 Procaspase expression has been evaluated in acute myelogenous leukemia. While one study showed that high levels of procaspase 2 and 3 portended a poor survival in adult AML, other studies have found no relationship between the absolute levels of these proteins and outcome in both lymphoid and non-lymphoid disease. [32] [33] [34] Again, these discordant results may be related to the fact that baseline protein expression might not be reflective of enzyme activity that is induced upon exposure of leukemic cells to therapy. Estrov et al 32 found that the levels of cleaved (and presumably active) caspase-3 correlated with a favorable outcome in AML.
Defects in apoptotic signaling in tumor cells may be a mechanism of escape from cancer chemotherapy. While static measurements of pro-and anti-apoptotic proteins at diagnosis and relapse have been informative, early changes in protein levels following chemotherapy may provide a better under-standing of how cancer cells die or defend themselves against the effects of treatment. Such information is essential in order to plan treatment strategies to modulate the apoptotic response. In the present study we examined changes in the profile of apoptotic protein expression in peripheral blood leukemia cells following the initiation of chemotherapy. Our primary goal in this pilot study was to determine whether leukemic blasts from individual patients execute apoptosis uniformly or whether diverse mechanisms account for tumor regression following the initial application of chemotherapy. Since the apoptotic response may be modulated by extracellular signals such as cytokines and/or stroma, we examined apoptosis in vivo. 35, 36 Blasts harvested from children with newly diagnosed or relapsed leukemia were analyzed for p53, MDM2, BCL-2, BCL-X L , BCL-X S and BAX protein expression and caspase-3 activity over a 24 h period after the start of therapy. Since apoptotic cells are removed rapidly from the circulation, we used an ex vivo assay to examine treatment-induced apoptosis. 37 We assessed the baseline 'apoptotic threshold', and the impact of subsequent treatment by comparing apoptosis induced by a 12 h ex vivo culture prior to the initiation of chemotherapy to apoptosis seen in blasts that were harvested 24 h after treatment was started and cultured using the same conditions. Our results indicate that the tempo and the underlying mechanisms of the apoptotic response differ greatly in individual cases of childhood leukemia. While some of this heterogeneity can be attributed to diverse subtypes of leukemia examined, we saw significant variability in the apoptotic response even in a cohort of patients who were classified and treated identically (eg clinical high risk early precursor B ALL).
Materials and methods

Study patients
Twenty-nine peripheral blood samples were obtained from 28 children diagnosed with leukemia from January 1998 to October 2000 after obtaining consent for participation in this Institutional Review Board-approved protocol (one patient was studied both at diagnosis and relapse). Patient characteristics are detailed in Table 1 . NCI standard criteria were used to classify patients as standard risk (age at diagnosis of 1-9.9 years and white cell count (WBC) Ͻ50 000/mm 3 ) or high risk (age у10 years and/or initial WBC у50 000/mm 3 ). 38 The majority of children were treated on open Children's Cancer Group (CCG) trials (CCG-1952 (CCG- , 1961 (CCG- , 2961 (CCG- and 1953 . The initial 24 h of induction therapy consisted of vincristine and prednisone for standard risk patients with acute lymphoblastic leukemia (ALL); vincristine, prednisone, and daunomycin or idarubicin for children with high risk ALL, infantile ALL or relapsed ALL; cytosine arabinoside, etoposide, 6-thioguanine, dexamethasone and daunomycin for patients diagnosed with acute myelogenous leukemia (AML) and acute undifferentiated leukemia (AUL).
Peripheral blood samples were drawn from an indwelling central venous catheter at 0, 1, 6 and 24 h following the initiation of chemotherapy. To be certain that tumor cells, not normal hematopoietic cells were analyzed, all patients had more than 50% circulating blasts at initial diagnosis or before the start of treatment. Tumor cells were further enriched through density gradient Ficoll-Hypaque PLUS (Pharmacia Biotech, Piscataway, NJ, USA) centrifugation. A pilot set of samples was examined after density gradient centrifugation and all contained more than 80% blasts (82-98%, data not shown). All samples were uniformly processed within 1 h of harvest to minimize additional apoptosis associated with sample storage and processing.
Determination of apoptosis
Tumor cells undergoing apoptosis in vivo are immediately removed by macrophages, so that their detection is not possible. 39 We therefore utilized an ex vivo assay for cell death as a surrogate measure of apoptosis in vivo. Cells were resuspended in 20% serum/RPMI 1640 media supplemented with 2 mmol/l glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin and were seeded at a density of 2 × 10 6 cells/ml in an atmosphere of 95% air/5% CO 2 at 37°C. Cells harvested at time-points 0 and 24 h were cultured for 12 h. The percentage of cells undergoing apoptotic death (expressed as the percentage of the total number of mononuclear cells in the sample) was measured using the terminal deoxynucleotidyl transferase (TdT) assay that detects free DNA termini, a byproduct of the apoptotic process. Leukemic blasts were washed with ice-cold phosphate-buffered saline (PBS) by centrifugation at 500 g for 5 min. Cells in suspension were fixed in 1 ml 1% paraformaldehyde for 15 min at 4°C followed by exposure to 70% ethanol at −20°C for a minimum of 1 h. 2 × 10 6 cells were resuspended in 50 l of 2.5 mM CoCl 2 , 1 nM biotin-16-dUTP, 0.1 U of terminal deoxynuleotidyl transferase (TdT) per l of cacodylate buffer (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA), and incubated at 37°C in a shaking H 2 O bath for 30 min. Cells were then resuspended in 100 l freshly prepared staining buffer, containing 2.5 g/ml of avidin conjugated to fluorescein isothiocyanate (FITC) (Boehringer Mannheim), 4× SSC (0.6 M NaCl/0.06 M sodium citrate), and 5% (w/v) non-fat dry milk. Cells were analyzed with a Becton Dickinson FacScan flow cytometer (San Jose, CA, USA). Data were stored in list mode files for subsequent off-line analysis using Modfit and WinList software (Verity Software, Topsham, ME, USA). Negative and positive controls consisted of HL-60 cells before and after 3 h of exposure to camptothecin (2 g/ml) (Sigma, St Louis, MO, USA) with and without TdT.
Western blot analysis of apoptosis-related protein expression in leukemic cells
The expression of p53, p21, MDM-2, BCL-2, BCL-X L , BCL-X S , BAX proteins was determined in peripheral blasts by Western blotting. For each time-point, whole-cell lysates were prepared in buffer containing 250 mM sucrose, 50 mM Tris (pH 7.4), 25 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 5 mM ␤-glycerolphosphate, 0.1% sodium deoxycholate, and 1 g/ml phenylmethylsulfonyl fluoride and proteinase inhibitors. Fifty micrograms of protein was separated by 7.5-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing conditions and transferred to a polyvinylidene difluoride (PVDF) membrane (BIO-RAD, Hercules, CA, USA). Monoclonal and polyclonal antibodies to the following proteins were used: p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p21 (Oncogene Research, Boston, MA, USA), and actin (Amersham Life Science, Arlington Heights, IL, USA). After incubation with the primary antibodies, membranes were washed and incubated with an appropriate second antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). The blots were then incubated with enhanced chemiluminescence ECL (Amersham Life Science) and exposed to film. Positive controls were included in each Western blot: p53 (p53 standard from Oncogene Research); p21, MDM-2, BCL-X L , BCL-X S and BAX (doxorubincin-induced MCF7 cells); BCL-2 (Jurkat cell lysate). Densitometric measurements were performed on scanned films using the 'ImageQuaNT software' (Molecular Dynamics, Sunnyvale, CA, USA). Densitometric values of individual protein levels were referenced to the time 0 value after normalization to actin. Therefore, 'fold' induction values following treatment were determined. The BAX: BCL-2 ratio was calculated by dividing the fold increase or decrease in BAX at 24 h by the fold increase or decrease in BCL-2. Pilot experiments were done on HL-60 cells to determine the conditions for linearity of the Western blot assays (data not shown). In considering the impact of apoptotic protein expression, we looked for Ͼ2-fold changes in protein expression during the first 24 h (eg at any time-point analyzed) following therapy that would account for the falling blast count observed in almost all patients.
Leukemia
Caspase-3 activity
Caspase-3 activity was measured directly in blasts at hours 0, 1, 6 and 24 following chemotherapy by a fluorometric assay based on the cleavage of unique peptide-MCA substrate. Samples were homogenized by sonication, and were mixed with 500 M DEVD-MCA (5 l) in microtiter plates and were agitated for 5 min at 37°C. At intervals over 2-4 h, samples were excited at 360 nm, and fluorescence emission at 460 nm was measured. Caspase-3 activity in (pmol/min/mg of protein) was proportional to the MCA fluorescence.
Statistical analysis
The correlations between the expression of p53, BCL-2, BAX, as well as the BAX:BCL-2 ratio and the percentage of peripheral blast decline were assessed by the Student's t-test. The simultaneous relationship between blast decline and the levels of BCL-X L and BCL-X S proteins was analyzed by the analysis of co-variance (ANOVA). For the analysis of apoptosis determination ex vivo as compared with p53 expression, the Fisher's exact test was used. A linear regression was used to analyze whether a correlation existed between enzyme activity over 24 h (ie area under the curve) and activity at specific time-points.
Results
Ex vivo apoptotic response to chemotherapy
Ex vivo culture assays were performed in 17 samples at hours 0 and 24 following the start of therapy. There was insufficient sample for this analysis in 12 patients. Before the initiation of chemotherapy, the baseline percentage of apoptotic cells at time 0 following 12 h in culture varied between 3% and 29%. Twenty-four hours following chemotherapy the percent of cells undergoing apoptosis increased from Ͻ1-38% ( Figure  1 ). A significant increase over baseline (Ͼ1.5-fold, range 1.7-4.7) in the percentage of apoptotic cells in culture was noted in nine patient samples following exposure to chemotherapy. Eight samples displayed a low level of apoptosis; Ͻ1.5-fold increase in apoptosis following chemotherapy or Ͻ10% of total cells undergoing apoptosis.
Expression of proteins in the p53 pathway after chemotherapy
The p53 apoptotic pathway was evaluated in 25 patient samples by determining p53, p21 and MDM-2 protein levels at baseline, and after the start of chemotherapy. Analyses could not be performed in four patient samples (Nos 21, 25, 26 and 28) due to insufficient quantity of purified blasts. Baseline p53 protein expression was seen in 21 of 25 analyzed samples prior to the initiation of chemotherapy (Nos 3, 5, 16 and 22 had no baseline expression). As expected, no increases in p53, p21 or MDM-2 protein expression were seen in leukemic blasts from the five standard risk patients whose initial treatment consisted of the non-p53-dependent drugs, vincristine and prednisone (data not shown).
A separate analysis was performed on 20 samples obtained from children who received at least one p53-dependent drug during the first 24 h of treatment (13 HR-ALL, one infant ALL,
Figure 1
Ex vivo apoptotic response to chemotherapy. Peripheral blood blasts were harvested at time 0 and 24 h following the onset of therapy and cultured in 20% RPMI with 2 mmol/l glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. The percent of apoptotic cells noted after 12 h was measured by TdT assay. There were two groups. (a) Low apoptotic group in which there is a low level of apoptosis; Ͻ1.5-fold increase in apoptosis following chemotherapy or Ͻ10% of total cells undergoing apoptosis. (b) High apoptotic group in which there are significant fold increases in the percent of apoptotic cells in culture; fold change Ͼ1.5. Light gray bars, time 0; dark gray bars, 24 h. SR-ALL, standard risk ALL; HR-ALL, high risk ALL; Inf-ALL, infant ALL; Rel-ALL, relapsed ALL. three AML, two relapsed ALL and one AUL), detailed in Table  2 . Diverse profiles of protein expression were seen among these patients during the initial 24 h of treatment. When segregating patients by the pattern of p53 expression, four major groups emerged (Table 2) . Representative profiles are shown in Figure 2 . Four patients showed no p53 expression during the initial 24 h of treatment (group 1). Three of 20 patients showed baseline expression without change following treatment and all three were T-ALL samples (group 2). The apparent increase in p53 in cases 11 (hour 1) and 29 (hour 6) as shown in Figure 2 was related to an increase in protein loading at these time-points. No increase was observed when the signal was normalized to actin. In two cases, a decline in initial baseline p53 expression was seen (group 3). Finally, in 11/20 samples at least a 2-fold increase in p53 expression over baseline was seen during the initial 24 h of treatment (Group 4). p53 appeared to be functional in cases showing up-regulation as the expression of its downstream mediator, p21 was also uniformly observed. Among the 11 patients in group 4, seven patients showed at least a 2-fold increase in the expression of two additional p53-regulated genes, MDM-2 and BAX. In two of these 11 patient samples, increased MDM-2 expression was seen without an increase in the expression of BAX while in two others no increase in expression of MDM-2 and BAX was observed despite up-regulation of p21. Interestingly, in some samples increased p21 and/or MDM-2 were seen without p53 expression (group 1).
These results demonstrate that at least two pathways of cell death operate in childhood leukemia that can be distinguished by p53 expression. This held true even for the uniformly classified and treated high risk ALL patients (indicated in parentheses in Figure 2 ). Of 13 such samples from children with high risk ALL, seven showed increased expression of p53 protein while six others showed either no baseline expression, no change in levels or decreased expression (Figure 2) . Fold increase over baseline. b The total cells undergoing apoptosis was less than 10% during the first 24 h following chemotherapy. nd, not done; +, protein expression at baseline, no change following treatment; −, no protein expression at baseline or following treatment; ↑/↓, Ͼ2-fold increase/decrease in protein expression.
Figure 2
p53, p21, MDM-2, and BAX protein expression in patients receiving p53-dependent drug during the initial 24 h of chemotherapy. Blasts show a diverse of pattern of protein expression following treatment. Western blot analysis was used to examine protein expression at time 0, 1, 6, and 24 h after chemotherapy. Twenty samples were obtained from children receiving at least one p53-dependent drug. Four groups emerged when segregating patients by the pattern of p53 expression. Group 1 (four patients): no p53 expression at baseline or following therapy; group 2 (three patients): p53 expression at baseline, no change following therapy; group 3 (two patients): down-regulation of p53 expression; group 4 (11 patients): up-regulation of p53 expression. Patterns are further subdivided within the four groups according to the expression of p53 target genes (p21, MDM-2 and BAX). A re-probing experiment with actin assesses for equal lane loading. +, protein expression at time 0, no change; ↑/↓; Ͼ2-fold increase/decrease in protein expression; −, no expression at hour 0 or following therapy; nd, not done (Nos 3 and 15 1 h time-point at BAX). Uniformly treated high risk ALL patients are shown in parentheses.
Correlation between p53 expression, rapidity of blast decline and ex vivo determinations of apoptosis
A correlation between p53 expression and the extent of apoptosis in culture was observed. Ex vivo culture assays were Leukemia performed in eight of the 11 patients (group 4) whose blasts showed an increase in p53 expression during the initial 24 h of therapy (Table 2 ). In seven of eight patients who showed increased p53 expression, a Ͼ1.5-fold increase in the percentage of apoptotic cells over baseline was seen after chemo-therapy was initiated. Ex vivo culture assays were also performed in seven of nine patients showing no increase in p53 expression after initiation of chemotherapy (groups 1-3). Six of these seven patients had 'low' (Ͻ1.5-fold change or Ͻ10% apoptosis) levels of apoptosis as determined by ex vivo culture assays. Thus, a significant correlation between up-regulation of p53 and ex vivo determination of apoptosis was seen (P = 0.010, Fisher's exact test). There was no statistical difference in blast decline over the first 24 h following chemotherapy between patients whose blasts showed increased p53 vs those without increased p53 expression (68% vs 46%, P = 0.16, ttest).
BCL-2 family pathway in childhood leukemia
Relative changes in the expression of anti-apoptotic proteins, BCL-2 and BCL-X L and pro-apoptotic BAX and BCL-X S proteins, over the first 24 h of treatment were determined (Table  3) in 25 of 29 patients. Analyses could not be performed in four patient samples (Nos 21, 25, 26 and 28) due to insufficient quantity of purified blasts. We examined the relationship between changes that would be expected to favor apoptosis and the rate of peripheral blast decline. BCL-2 protein was detected at hour 0 in all patients. Levels decreased (Ͼ2-fold) in six of 25 samples during the first 24 h of therapy (Figure 3) . Over the initial 24 h of therapy the average peripheral blast declined was 63% in six patients where BCL-2 decreased, vs 50% in 19 patients with no significant change in BCL-2 expression (P = 0.
44, t-test).
Expression of the pro-apoptotic protein BAX was detected at baseline in all 23 samples where it was analyzed. A 2-fold increase in BAX expression was seen in 11 samples. The average peripheral blast decline in 11 patients with BAX up-regulation was 58% over the initial 24 h of therapy vs 44% in 13 patients with no change or decrease in BAX expression (P = 0.36, t-test) ( Table 3) . Because the ratio of BAX to BCL-2 rather than the absolute levels of BCL-2 is thought to be important for apoptosis, we also determined the BAX:BCL-2 ratio at hour 24. The average blast decline correlated positively with the BAX:BCL-2 ratio. An average blast decline of 68% was seen in eight patients where the BAX: BCL-2 increased by 2-fold (favoring apoptosis) vs 42% in 15 patients without an increase in BAX:BCL-2 ratio (P = 0.07, t-test) ( Table 3) .
In contrast to BCL-2 and BAX where uniform baseline expression was seen in all patients, five and seven patients, respectively, showed no expression of BCL-X L and BCL-X S at baseline. Subsequent changes in BCL-X L and BCL-X S expression during the initial 24 h of therapy were variable (Table 3) . No distinct correlation between decreases in BCL-X L , or increases in BCL-X S expression, and the peripheral blast decline was seen (P = 0.88, and P = 0.83, respectively, ANOVA).
Caspase-3 activity
Caspase-3 activity was measured in (pmol/min/mg) in 15 patients prior to, and following the onset of chemotherapy. Since the profiles varied widely, we integrated the activity (area under the curve over 24 h after normalizing to time 0 activity) and observed values ranging from 41 to 3249 pmol-h/min/mg protein ( Figure 4 ). This diversity in caspase-3 activity was seen even among the subset of five uniformly treated patients with high-risk ALL (Nos 15, 18, 19, 22 and 27). Interestingly, there was a poor correlation between initial caspase-3 activity measured before chemotherapy and an increase following treatment (r = 0.28, P = 0.31). However, following the onset of chemo-
Figure 4
Caspase activity in childhood leukemia. Caspase-3 activity was measured in pmol/min/mg protein in 15 patients (13 ALL patients and two AML patients) during the first 24 h following chemotherapy. Activity was integrated (area under the curve after normalizing to time 0 activity) and values ranged from 41 to 3249 pmolh/min/mg protein.
therapy, the 24 h area under the curve correlated with the caspase activity at hours 6 (r = 0.90, P Ͻ 0.0001); and 24 (r = 0.74, P = 0.002) but not at hour 1 (r = 0.14, P = 0.63). No significant correlation between caspase-3 activity and p53 expression or peripheral blast decline was seen.
Discussion
Chemotherapeutic agents, especially when used in the context of therapy for hematopoietic tumors, exert their effect by inducing apoptosis. In general, these drugs damage cellular DNA, initiating a cascade of intracellular events leading to cell death. While a number of previous studies have focused on determining the prognostic value of 'baseline' levels of protein that make up components of the apoptotic pathway, the purpose of this pilot study was to determine if blasts die through a relatively uniform cell death pathway, and to assess the magnitude of changes in the levels of proteins following treatment. Blasts were harvested and processed immediately to avoid artifacts associated with prolonged ex vivo exposure and processing.
Our results show significant variation in the apoptotic profile of childhood leukemia cells. While some of this variation may due to examination of different subtypes of leukemia and modes of therapy, we saw significant variation even among identically classified and treated high risk ALL patients. Host factors such as polymorphisms of drug metabolizing genes are also likely to impact the apoptotic response since these variables would influence the timing and magnitude of the initial apoptotic stimulus. [40] [41] [42] [43] [44] However, despite any potential differences in drug pharmacokinetics, the apoptotic response was initiated in all patients with three exceptions since blast counts fell significantly within 24 h following the start of treatment. Thus the character of the apoptotic pathway could be assessed.
The rapidity of initial response to chemotherapy as deterLeukemia mined by remaining percentages of bone marrow and circulating blasts at day 7, correlates with ultimate outcome. 45, 46 This observation indicates the importance of early differences in chemosensitivity. We hypothesized that the rapidity and structure of the apoptotic response within the first 24-48 h may also predict relapse-free survival. This pilot study was undertaken to acquire the background information necessary to begin to develop approaches whereby the apoptotic response in vivo might be evaluated in a large cohort of children undergoing therapy on clinical trials. As expected, patients in this study experienced a dramatic decline in blast count after chemotherapy was initiated. The major finding of this study is that two pathways of apoptosis were identified that could be distinguished from one another by the expression of p53. Moreover, only a minority of samples studied showed changes in the expression of BCL-2, BAX, BCL-X L and BCL-X S that favored apoptosis, but those individuals whose blasts showed an increased BAX/BCL-2 ratio appeared to have a more dramatic fall in blast count. Direct detection of apoptosis in leukemic cells harvested from the circulation is not possible due to their removal in vivo by macrophages 47, 48 and we therefore relied on an ex vivo assay to determine the sensitivity of blasts to apoptosis. Like other investigators, we observed wide variability in baseline apoptosis presumably initiated by absence of exogenous growth factors and stromal contact in our culture system. In agreement with other studies, we noted that two of three AML cases displayed lower levels of apoptosis but in contrast to the report by Kumar et al, 49 T cell cases were similar to B precursor ALL. 50 Ito and colleagues 51 also noted wide variability in leukemia cell survival after culture on a stromal cell layer. Blasts with a hyperdiploid karyotype, a feature correlated with a good prognosis, had poor survival whereas those blasts harboring an adverse cytogenetic translocation had significantly increased survival. We cultured leukemic blasts under much more adverse conditions that could be predicted to reduce the effect of subtle differences in apoptotic threshold among blasts from different patients. However, using a more straightforward assay we also observed wide variability in the percent of cells undergoing apoptosis before exposure to treatment. Most cells showed an increase in apoptosis after exposure to chemotherapy. Apoptosis as determined by ex vivo culture correlated significantly with p53 expression. The reason for this association is uncertain but blasts that up-regulate p53 might be more sensitive to growth factor withdrawal and/or lack of stromal contact.
A major finding of our study was the identification of two pathways of apoptosis that can be distinguished from one another by the up-regulation of p53 expression. Twenty patients received at least one p53-dependent drug, and 11 of these patients demonstrated an increase in p53 protein level 24 h after the start of chemotherapy. p53 appeared functional as its target, p21, was up-regulated in all patients who showed increased p53 expression. Our results showed that most samples with up-regulation of p53 also showed increased expression of MDM-2. The magnitude of the response, however, was quite variable. Like p21, MDM-2 is also transcriptionally regulated by p53 as part of a negative feedback loop. Over-expression of the MDM-2 protein represents an alternative mechanism of p53 inactivation in human malignancies, and elevated levels of MDM-2 have been detected in relapsed and high risk leukemic cell lines. 14, 15, 52, 53 It might be anticipated that samples with minimal MDM-2 expression would display more apoptosis, while those with greater MDM-2 expression might have a blunted response. In our pilot study we did not find a correlation between MDM-2 levels, caspase-3 activity and/or rapidity of blast decline in the initial 24 h of therapy. In agreement with other studies, two patients who did not express p53 showed expression of MDM-2, suggesting that p53-independent pathways may also lead to increased expression of MDM-2. 54 Apoptotic cell death also appeared to occur through nonp53-dependent mechanisms. No increase in p53 expression over baseline was seen in approximately half of the patients who received p53-dependent drugs. However, the vast majority of these patients still showed a decrease in peripheral blood blasts. Elevated p53 protein at baseline with no change following exposure to chemotherapy has been a signature of p53 mutations that block function. This pattern was seen in three patients (all three were from patients with T-ALL). The incidence of p53 mutations in childhood ALL at diagnosis is low (Ͻ3%) 55 although it has been reported in up to 16% of patients at relapse. 56 Similarly, although the incidence of p53 mutations is high in T-ALL cell lines, mutations are infrequent in clinical samples at diagnosis. 57 Given the low incidence of p53 mutations it would seem unlikely that the pattern of p53 expression observed in blasts from three T-ALL patients would be due directly to p53 mutations. However, p53 stabilization and impairment of transcriptional activity has been noted in adult T cell leukemia/lymphoma. 58 Previous studies have also defined two general apoptotic pathways. In one circumstance, a mitochondrial pathway is activated, usually in response to up-regulation of p53. 59 The release of cytochrome c leads to formation of the apoptosome, a complex composed of APAF-1, ATP and procaspase-9.
60
Activated caspase-9, an initiator caspase, then processes procaspase 3. This results in activation of caspase-3. 29 Alternatively, or in concert with the mitochondrial pathway, cytotoxic therapy can result in activation of death receptor signaling pathways such as CD95/Fas-CD95 ligand interaction. 61 However, the contribution of this pathway to chemotherapyinduced cell death in leukemia is controversial. 62, 63 A recent report by Wieder et al 64 showed that in vitro apoptosis of childhood pre-B blasts in response to epirubicin was CD95/Fas independent even though caspase 8 was activated. Although the nature of the p53-independent pathway remains to be defined, our results indicate that one of two (or more) mechanisms is used in individual cases of childhood leukemia.
In agreement with other studies, we observed BCL-2 expression in all samples collected at the time of diagnosis. Previous reports have failed to show a correlation between BCL-2 levels and remission rates and outcome in childhood ALL although high BCL-2 levels were associated with a slow early response for T cell ALL in one study. 65, 66 Using a different experimental approach we showed that a decrease in BCL-2 expression was observed only in a minority of samples (6/25) despite regression of the peripheral blasts. Taken together, these results indicate that changes in BCL-2 protein levels do not play a major role in apoptosis in most cases of childhood leukemia. BAX is a pro-apoptotic protein whose expression is regulated by p53. 67 BAX antagonizes the ability of BCL-2 to block apoptosis. Several investigators have shown that the BAX:BCL-2 ratio correlates with drug response. 22, 24, [68] [69] [70] [71] An increased (favorable) ratio correlated with more rapid clearance of blasts in our study, although this did not reach statistical significance, likely due to small patient numbers.
Variability in the expression of BCL-2 family members suggests that there is no uniform cell death pathway involving these proteins in childhood leukemia. Cell death in individual cases could be caused by changes in levels of the proteins studied in this investigation. However, the fact that many samples showed no change in the relative levels of BCL-2, BCL-X L , BAX, and BCL-X S , despite a falling peripheral blood blast count, indicates that early apoptotic death following treatment may not uniformly involve these proteins. However, we did not examine potential changes in the subcellular distribution of these proteins. [72] [73] [74] Even though we did not observe changes in levels of BCL-2 family members in most cases, modulation of these proteins might still be considered as an option for enhancing the effectiveness of conventional chemotherapy. For example the high BCL-2 expression observed in most cases could afford a protective effect against druginduced apoptosis. Decreasing levels through emerging antisense technology may prove to be highly successful. 75 Caspases are key effectors of cellular death and have been implicated as predictors of survival in AML and ALL. 32, 76 In particular, caspase-3 has been shown to be involved in the apoptosis seen in leukemia in response to many chemotherapeutic agents. In our study, we used caspase-3 as a parameter for apoptosis and noted wide variability in activity. Our sample size was too small to detect any significant association with clinical response. However, it should be noted that baseline expression did not correlate with activity over the first 24 h following chemotherapy. Therefore, the measurement of baseline caspase-3 activity, a parameter examined in previous studies, may be a poor reflection of the increased activity following treatment. 32, 76 In our study, there was a significant correlation between the caspase-3 activity over 24 h (ie area under the curve) and activities at hours 6 and 24. Therefore, measurement at one of these time-points might be suitable for analysis in the context of a large clinical trial.
In summary, our data show that childhood leukemic blasts undergo treatment-induced apoptosis through diverse mechanisms. Analysis of a larger group of patients may allow the identification of patterns and define relative defects predictive of outcome. The more controlled but labor-intensive approach used in our pilot protocol would be impractical in the context of a large clinical trial. Moreover, limiting analysis only to those patients with high circulating blasts would exclude a large number of patients from study. We are currently optimizing a fluorescence-activated cell sorter approach where surface labeling of an appropriate leukemia-associated antigen (eg CD19, CD5) in conjunction with intracellular staining with anti-p53, anti-BCL-2, anti-BAX, etc. antibodies could provide specific analysis of a subpopulation of blasts within a normal background. Alternatively, blasts might be purified from the peripheral circulation by cell sorting using FACS or immunomagnetic bead approaches. In our study, samples were processed immediately to avoid artifacts associated with survival ex vivo. Analysis of clinical samples from cooperative group trials will need to take this issue into consideration. Preliminary experiments indicate that significant apoptosis occurs ex vivo during transport. However, the relative fold-change over time seems to be preserved. Lastly, almost all samples showing changes in protein expression did so by 6 and 24 h so that analysis at either time-point would be informative.
